NASDAQ$SMTI
Sanara MedTech Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Sanara MedTech reported record revenue driven by increased product recognition and team efforts.
Sanara MedTech Inc. announced its third quarter 2022 results, highlighting a record revenue achievement driven by increased product recognition. The company is integrating Scendia Biologics and has formed a new chronic wound care partnership with InfuSystem Holdings, Inc.
- Achieved record revenue for the third quarter of 2022.
- Revenue record for the historical business before the acquisition of Scendia Biologics.
- Integrating Scendia into the Company.
- Announced a new chronic wound care partnership with InfuSystem Holdings, Inc.
Headline financials
Revenue & EPS history
Sanara MedTech · Revenue · Quarterly
$13M
Revenue by segment
Sanara MedTech · $31.6M total across 2 segments · Q2 2023
- Soft tissue repair$15.8M—50.0%
- Bone fusion products$15.8M—50.0%
Forward guidance
The company looks forward to further integrating Scendia into its business and working with InfuSystem to continue providing solutions that improve outcomes and reduce costs of care.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+0.1%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.6%
Avg return
30 days after
34%
22 / 65 earnings
Positive
+28.6%
Q4 2014
Best reaction
-25.0%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.3% | -12.1% | — | |
| Q1 2026 | +13.0% | +17.3% | +19.5% | |
| Q3 2025 | -23.4% | -24.9% | -7.6% | |
| Q2 2025 | -4.8% | -3.3% | +6.4% | |
| Q1 2025 | -9.0% | -11.2% | -17.9% | |
| Q4 2024 | -12.6% | -15.4% | -10.4% | |
| Q3 2024 | +6.3% | -1.0% | +2.5% | |
| Q2 2024 | +14.9% | +16.3% | +20.2% | |
| Q1 2024 | -5.0% | -2.9% | -0.5% | |
| Q4 2023 | -1.8% | -1.1% | -13.1% | |
| Q3 2023 | +18.8% | +15.3% | +37.5% | |
| Q2 2023 | -12.5% | -13.6% | -22.6% | |
| Q1 2023 | -5.0% | -9.2% | -5.9% | |
| Q4 2022 | -0.1% | -4.1% | +17.9% | |
| Q3 2022 | +4.1% | +7.2% | +3.2% | |
| Q2 2022 | +1.2% | -1.7% | +13.4% | |
| Q1 2022 | +5.0% | +2.3% | -12.2% | |
| Q4 2021 | +2.5% | +10.7% | -10.9% | |
| Q3 2021 | -1.6% | -2.2% | -15.8% | |
| Q2 2021 | -8.3% | -12.4% | -14.5% | |
| Q1 2021 | +5.2% | +14.9% | +28.7% | |
| Q4 2020 | +14.5% | +6.8% | -4.5% | |
| Q3 2020 | -4.5% | -4.3% | +15.7% | |
| Q2 2020 | +9.8% | +13.7% | +37.2% | |
| Q1 2020 | -20.7% | -18.2% | +28.8% | |
| Q4 2019 | -4.3% | +7.3% | +30.9% | |
| Q3 2019 | -3.9% | -5.7% | +5.1% | |
| Q2 2019 | -11.5% | -20.1% | -17.2% | |
| Q1 2019 | +0.0% | -16.7% | -16.7% | |
| Q4 2018 | +0.0% | -16.7% | -16.7% | |
| Q3 2018 | +0.0% | +0.0% | +0.0% | |
| Q2 2018 | -10.0% | -10.0% | -30.0% | |
| Q1 2018 | +20.0% | +0.0% | +20.0% | |
| Q4 2017 | +20.0% | +0.0% | +20.0% | |
| Q3 2017 | +0.0% | +0.0% | -14.3% | |
| Q2 2017 | +0.0% | +16.7% | +16.7% | |
| Q1 2017 | +0.0% | +0.0% | -22.2% | |
| Q4 2016 | +0.0% | +0.0% | -10.0% | |
| Q3 2016 | -20.0% | -20.0% | +0.0% | |
| Q2 2016 | +20.0% | +0.0% | +0.0% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +11.1% | — | — | |
| Q4 2014 | +28.6% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +14.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +16.7% | — | — | |
| Q4 2012 | -12.5% | — | — | |
| Q3 2012 | -16.7% | — | — | |
| Q2 2012 | +6.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -10.3% | — | — | |
| Q1 2011 | -11.1% | — | — | |
| Q4 2010 | +3.1% | — | — | |
| Q3 2010 | -25.0% | — | — | |
| Q2 2010 | +2.9% | — | — | |
| Q1 2010 | +5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro